Abstract 183P
Background
Personalized targeted cancer treatment strongly depends on genetic tests in tumor tissue. Meanwhile, it is essential to understand the oncogenicity of a large number of somatic and germline variants to identify potential drug targets, which can be used for further treatment. An adopted classification scheme to guide variant oncogenicity assessment has to be easy, fast and reproducible. In this study we implemented a full-fledged database SomaVar and web-based frontend for somatic variant upload, annotation and classification using the VICC classification guidelines.
Methods
The frontend provides a multitude of utility functions which include an advanced variant search, user defined variant lists, automatic classification criteria selection and extensive administrative utilities. SomaVar supports variant annotation including in-silico pathogenicity prediction scores, splicing prediction scores, third party classifications, population scores and protein domains. SomaVar has a semi-automatic classification algorithm for oncogenicity based on the VICC standards and allows harmonized consensus classification between different users.
Results
Using a list of variants already classified by experts we show that the automatic classification algorithm provides a high-quality preselection for most VICC criteria. This not only increases the speed at which experts can classify variants, but also increases quality by mitigating human error. We also compared our knowledgebase to OnkoKB. A large overlap was found within the both groups of variants of likely oncogenic and of unclear oncogenicity variants. Interestingly, divergent classification was observed for variants located within splice regions and for benign variants listed in gnomAD at high allele frequencies.
Conclusions
To date, our knowledgebase harbors over 20.000 classified somatic variants and continues to grow. This open-source knowledgebase is publicly available online.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract